GPP drug safety study in korea withdrawn before starting
NCT ID NCT06886009
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 23 times
Summary
This study was designed to track the safety and effectiveness of spesolimab in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. It planned to enroll patients starting spesolimab for the first time in routine care. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ajou University Hospital
Suwon, 16499, South Korea
-
Asan Medical Center
Seoul, 05505, South Korea
-
Pusan National University Yangsan Hospital
Busan, 49241, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
Conditions
Explore the condition pages connected to this study.